Allergic reactions and anaphylaxis
Patent Blue V is a well-documented cause of IgE-mediated allergic reactions. Clinical reports from sentinel lymph node biopsy procedures, where the dye is injected directly, show anaphylaxis rates of roughly 0.4 to 0.5 percent. Reactions range from skin rashes and low blood pressure to cardiovascular collapse. Prior sensitisation through food or everyday products containing the dye appears to be the route by which people develop IgE antibodies that then trigger reactions on later exposures. The mechanism is not fully settled: IgE-mediated mast cell activation is the leading explanation, but direct mast cell activation without prior IgE sensitisation is also possible.
In a series of breast cancer patients undergoing sentinel node biopsy, 0.5% had allergic reactions to Patent Blue V and 0.4% experienced anaphylaxis specifically, characterised by cardiovascular and cutaneous symptoms with poor response to ephedrine.
2006ObservationalLaurie SA et al., Adverse reactions to patent blue V dye, New Start and Almanac trials
Anaphylaxis to Patent Blue V in a surgical series showed incidence of any reaction at 0.1 to 2.8 percent, with severe anaphylactic shock at approximately 0.06 percent; most cases are IgE-mediated mast cell activation.
2022ObservationalFrontiers in Oncology case series and review
Genotoxicity: open questions remain
The 2013 EFSA food additive re-evaluation found no evidence of genotoxicity using in vivo micronucleus and comet assays, and the 2021 human lymphocyte study also found no significant genotoxic effects. However, the 2024 EFSA feed additive renewal assessment identified a specific data gap: no adequate data exist on the potential of Patent Blue V to cause numerical chromosomal damage (aneugenicity). EFSA's FEEDAP Panel stated it could not rule out genotoxicity on this basis and recommended minimising user exposure. This gap applies specifically to a feed-use renewal application and does not overturn the 2013 food-use conclusion, but it is an unresolved question.
EFSA's 2013 food additive re-evaluation concluded that Patent Blue V at purity above 90% showed no genotoxic concern based on negative in vivo micronucleus and comet assay results.
2013Regulatory reviewEFSA ANS Panel, Scientific Opinion on re-evaluation of Patent Blue V (E131) as a food additive, EFSA Journal 11(3):2818
A 2021 study in human peripheral lymphocytes found no significant genotoxic or cytotoxic effects from Patent Blue V, though the authors noted further testing with different endpoints would be needed.
2021LabDrug and Chemical Toxicology, Vol 45, No 4
EFSA's 2024 feed additive renewal assessment found the potential for numerical chromosomal damage (aneugenicity) had not been adequately investigated and concluded genotoxicity could not be ruled out, recommending renewal authorisation not be granted.
2024Regulatory reviewEFSA FEEDAP Panel, EFSA Journal 2024, doi:10.2903/j.efsa.2024.8722
Exposure in children may exceed the ADI at maximum permitted levels
When EFSA modelled dietary exposure in 2013, it found that at the maximum permitted use levels set in EU law, high consumers among toddlers and children could exceed the ADI of 5mg per kg body weight per day. At maximum reported actual use levels in food products, exposure for all population groups stayed below the ADI. This means the margin is tighter for young children who eat a lot of brightly coloured sweets and drinks.
At maximum permitted use levels, dietary exposure estimates for high consumers among toddlers and children exceeded the ADI of 5mg/kg bw/day; at maximum reported actual use levels, all population groups remained below the ADI.
2013Regulatory reviewEFSA ANS Panel, Scientific Opinion on re-evaluation of Patent Blue V (E131) as a food additive, EFSA Journal 11(3):2818
Not approved in the US, Canada or Australia
Patent Blue V has never been approved as a food colour by the US FDA, and is also not permitted in Canada or Australia. The primary grounds cited across these jurisdictions are the allergic reaction risks and insufficient evidence of full safety. It remains permitted in the UK, EU and Norway under specific conditions.
Patent Blue V is not on the US FDA list of colour additives approved for use in food. It is similarly not on Canada's List of Permitted Food Colours or Australia's permitted food additives list.
RegulatoryUS FDA Colour Additives Status List; CFIA permitted food colours table; multiple regulatory comparisons